Novanta (NOVT) Earnings Date & Reports

Key Takeaways

• Novanta reported third-quarter 2026 revenue of $305.0 million, up 23.1% year over year, topping consensus estimates.
• Adjusted diluted earnings per share (EPS) rose 21% to $1.05, beating analyst expectations, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 38% to $80.3 million.
• GAAP (Generally Accepted Accounting Principles) net income fell to $2.0 million, or $0.05 per share, reflecting costs tied to the company's largest-ever acquisition.
• Customer bookings increased 29%, lifting backlog to $543 million and signaling continued commercial momentum.
• Management issued fourth-quarter 2026 revenue guidance of $306 million to $312 million but modestly lowered full-year adjusted EPS guidance.
• For additional context, explore Novanta's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Investors can also discover AI-driven trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Novanta is a technology partner to medical and advanced technology equipment manufacturers, serving customers across precision medicine, precision manufacturing, robotics and automation, and advanced surgery. Its third-quarter 2026 report carried outsized significance because it marked the first full quarter following the completion of the company's largest acquisition in its history. That deal meaningfully reshapes Novanta's revenue base and product portfolio, making this earnings release an important test of how smoothly the integration is proceeding and whether the acquired business is tracking expectations. For investors, the results offered a read on demand across healthcare and advanced industrial markets, the durability of recent momentum, and management's confidence heading into the end of the fiscal year.

Reported Results

Novanta reported third-quarter 2026 GAAP revenue of $305.0 million, a 23.1% increase from $247.8 million in the prior-year period and slightly above consensus estimates. By segment, Automation Enabling Technologies revenue reached $145 million, while Medical Solutions revenue totaled $160 million.

Adjusted diluted EPS rose 21% to $1.05, above analyst expectations, and adjusted EBITDA increased 38% to $80.3 million, representing a 26% margin that improved 290 basis points year over year. On a GAAP basis, however, net income declined to $2.0 million, or $0.05 per diluted share, versus $10.7 million, or $0.30 per share, a year earlier, as acquisition-related and integration costs weighed on reported profitability. GAAP operating margin narrowed to 4.6% from 11.5%.

Customer bookings rose 29%, and backlog expanded to $543 million. The company guided fourth-quarter 2026 GAAP revenue to a range of $306 million to $312 million and full-year GAAP revenue to $1.135 billion to $1.140 billion, while modestly trimming its full-year adjusted EPS outlook to a midpoint of $3.69.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings movers like Novanta, it offers a practical way to identify comparable names and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Heading into the release, sentiment was cautiously optimistic, with analysts anticipating strong revenue growth driven by the completed acquisition. The headline results largely supported that view: revenue and adjusted EPS both exceeded consensus, and adjusted EBITDA expanded sharply. At the same time, the decline in GAAP profitability and the modest downward revision to full-year adjusted EPS guidance tempered enthusiasm. The stock traded lower in after-hours activity following the announcement, reflecting investor focus on the integration costs and the softer fourth-quarter EPS outlook relative to some estimates. Overall, the market appeared to weigh strong top-line momentum and robust bookings against near-term margin and profitability pressures tied to the acquisition.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching how effectively Novanta integrates its recent acquisition and captures the operational synergies management has cited. The deal brings new products and end markets, but it also introduces integration expenses that have pressured GAAP profitability in the near term. Progress on cost discipline and margin recovery will be a central theme in coming quarters.

Demand signals remain encouraging. Bookings growth of 29% and a backlog of $543 million suggest solid commercial momentum heading into 2027. Management has also pointed to growth platforms in robotic surgery, precision robotics, warehouse automation, and physical AI (artificial intelligence applied to real-world robotic and automation systems), areas it views as significant long-term opportunities.

Key factors to monitor include the pace of backlog conversion into revenue, gross and operating margin trends as acquisition-related costs roll off, and any further updates to full-year guidance. Currency movements and broader conditions in healthcare and advanced industrial markets will also influence results. Investors will be looking for confirmation that the company can sustain double-digit growth while gradually restoring profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations